A CERTIFIED TRUE COPY - 03 294-JFK

Document 1

Filed 04/25/2007

Page 1 of 2

JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

APR 1 9 2007

MULTIDISTRICT LITIGATION

07 CV DOCKET NO. 1789

3294

E FILED CLERK'S OFFICE

BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE FOSAMAX PRODUCTS LIABILITY LITIGATION

Nancy Ferraro, et al. v. Merck & Co., Inc., et al., C.D. California, C.A. No. 2:06-7733 Jennifer Bogard, et al. v. Merck & Co., Inc., et al., N.D. California, C.A. No. 3:06-6917 Edna Goya v. Merck & Co., Inc., et al., S.D. California, C.A. No. 3:06-2574

BEFORE WM. TERRELL HODGES, CHAIRMAN, D. LOWELL JENSEN, J. FREDERICK MOTZ,* ROBERT L. MILLER, JR., KATHRYN H. VRATIL, DAVID R. HANSEN* AND ANTHONY J. SCIRICA,* JUDGES OF THE PANEL

TRANSFER ORDER

Before the Panel are motions brought, respectively, pursuant to Rule 7.4, R.P.J.P.M.L., 199 F.R.D. 425, 435-36 (2001), by plaintiffs in a Central District of California action, a Northern District of California action, and a Southern District of California action. These plaintiffs ask the Panel to vacate its orders conditionally transferring the actions to the Southern District of New York for inclusion in the coordinated or consolidated pretrial proceedings occurring there in this docket. Common defendant Merck & Co., Inc., opposes the motions to vacate and urges inclusion of the actions in the MDL-1789 proceedings.

On the basis of the papers filed and hearing session held (without oral argument), the Panel finds that these actions involve common questions of fact with the actions in this litigation previously transferred to the Southern District of New York, and that transfer of these three actions to the Southern District of New York for inclusion in the coordinated or consolidated pretrial proceedings in that district will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. The Panel further finds that transfer of these actions is appropriate for reasons expressed by the Panel in its original order directing centralization in this docket. In that order, the Panel held that the Southern District of New York was a proper Section 1407 forum for actions involving allegations that ingestion of Fosamax, a prescription medication used in the treatment of osteoporosis, caused adverse effects, in particular, osteonecrosis of the jaw. See In re Fosamax Products Liability Litigation, 444 F.Supp.2d 1347 (J.P.M.L. 2006). Should plaintiffs wish to pursue or renew their motions for remand to state court, they can do so in the transferee court. See, e.g., In re Ivy, 901 F.2d 7 (2nd Cir. 1990); In re Prudential Insurance Company of America Sales Practices Litigation, 170 F.Supp.2d 1346, 1347-48 (J.P.M.L. 2001).

Judges Motz, Hansen and Scirica took no part in the decision of this matter.

A CERTIFIED COPY

J. MICHAEL MCMAHON,

CLERK

Y

- 2 -

IT IS THEREFORE ORDERED that, pursuant to 28 U.S.C. § 1407, these actions are transferred to the Southern District of New York and, with the consent of that court, assigned to the Honorable John F. Keenan for inclusion in the coordinated or consolidated pretrial proceedings occurring there in this docket.

FOR THE PANEL:

Wm. Terrell Hodges Chairman